

Docket No.: 0019240.00596US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Andrew R. Marks et al. Confirmation No.: 7653
Application No.: 10/809,089 Art Unit: 4173
Filed: March 25, 2004 Examiner: B. J. Packard
Title: NOVEL ANTI-ARRHYTHMIC AND HEART FAILURE DRUGS THAT
TARGET THE LEAK IN THE RYANODINE RECEPTOR (RyR2)
AND USES THEREOF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

Dear Sir:

This Supplemental Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits and before the mailing date of a final Office Action or a Notice of Allowance.

Please charge the \$180.00 fee to our Deposit Account No. 08-0219.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Respectfully submitted,

Dated: January 13, 2009

/Jane M. Love, Ph.D./
Jane M. Love, Ph.D.
Registration No.: 42,812
Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP
399 Park Avenue
New York, New York 10022
(212) 230-8800 (telephone)
(212) 230-8888 (facsimile)